An FDA advisory committee on Friday is scheduled to discuss the potential of leukocyte growth factors from Amgen, Teva Pharmaceutical Industries and Sanofi in treating radiation exposure from a nuclear accident or attack. The drugs -- Neupogen and Neulasta from Amgen, Tbo-filgrastim from Teva and Leukine from Sanofi -- work by increasing white blood cell levels. The treatments could reduce mortality after radiation exposure, according to agency documents.

Full Story:

Related Summaries